Case studyRiboflavin treatment in a case with l-2-hydroxyglutaric aciduria
Introduction
L-2-hydroxyglutaric aciduria (LHGuria) (OMIM:236792) is one of the chronic progressive neurodegenerative disorders in the group of organic acidurias. The disorder has a remarkably consistent clinical, biochemical and neuroradiological pattern.1 Clinically, the disease is characterized by psychomotor delay followed by cerebellar ataxia, dysarthria, moderate-to-severe mental deterioration and macrocephaly. Extrapyramidal (dystonia, choreic movements), pyramidal (spastic paresis) and pseudobulbar signs and seizures may also occur. It is usually diagnosed in infancy and childhood, and has a slowly progressive course extending well into adolescence and adulthood. However, it might be diagnosed in the neonatal period or in the adulthood as well. Different from other organic acidurias, LHGuria is potentially associated with central nervous system tumors. Magnetic resonance imaging (MRI) characteristically shows leukodystrophic abnormalities, and abnormal signals in dentate nuclei and basal ganglia. The diagnosis of LHGuria depends on detecting increased levels of LHG in urine by means of gas chromatography–mass spectrometry.
Although LHGuria is a rare neurometabolic disease, many significant findings have been reported recently.2, 3, 4, 5 The mutated gene has been localized on chromosome 14q22, and many different mutations have been detected.2 Rzem et al.3 demonstrated that LHG was metabolized in rat tissues by a membrane-bound mitochondrial dehydrogenase, which catalyzes specifically the oxidation of L-2-hydroxyglutarate to alpha-ketoglutarate (Fig. 1). The gene that had been linked to LHGuria has been detected to encode a mitochondrial membrane-bounded enzyme, LHG dehydrogenase (EC 1.1.99.2). Furthermore, this enzyme in rat liver was stimulated by flavin-adenine dinucleotide (FAD), which suggests that FAD serves as a cofactor. It has also shown that the enzyme produced in human embryonic kidney cells transfected with a cDNA encoding the product of the human gene had similar biochemical characteristics as the rat liver enzyme.4 LHG dehydrogenase activity in those transfected cells was modestly stimulated by FAD. Given the latest finding, riboflavin deserves to be evaluated as a potential treatment modality in LHGuria. In this report, we present a case with LHGuria and changes occurring in the clinical and laboratory findings during nearly 2 years of riboflavin treatment.
Section snippets
Case report
The patient was referred to our department because of gait disturbance, speech difficulty and mental retardation when he was a 16-year-old. He was born from Turkish nonconsanguineous parents. The parents described developmental delay in his motor, social and language skills since his infancy, but they thought that his developmental delaying had been secondary to his low birth weight. He was not able to walk independently until 3 years of age. Besides walking difficulties, impaired language
Discussion
Riboflavin is the cofactor of FMN and FAD, which acts as electron carriers in redox reactions in human metabolism. It is involved in many metabolic disorders and has been considered in the treatment of several inborn errors of metabolism such as Glutaric aciduria I, mild variants of electron transfer flavoprotein dehydrogenase, short chain acyl CoA dehydrogenase and congenital lactic acidosis, complex I deficiency.6 Moreover, riboflavin has been noted increasingly in various disorders such as
Acknowledgements
The author thanks for Prof. Turgay Coşkun and Prof. Meral Topçu for their great contribution to our evaluation of this case.
References (11)
- et al.
The gene mutated l-2-hydroxyglutarate dehydrogenase encodes l-2-hydroxyglutarate dehydrogenase
Biochimie
(2006) Riboflavin (vitamin B-2) and health
Am J Clin Nutr
(2003)- et al.
Riboflavin-responsive glutaryl CoA dehydrogenase deficiency
Mol Genet Metab
(2006) - et al.
L-2-hydroxyglutaric acid inhibits mitochondrial creatine kinase activity from cerebellum of developing rats
Int J Dev Neurosci
(2003) - et al.
L-2-hydroxyglutaric aciduria: a report of 29 patients
Turk J Pediatr
(2005)
Cited by (47)
Glutaric aciduria and L-2-hydroxyglutaric aciduria: Clinical and molecular findings of 35 patients from Turkey
2023, Molecular Genetics and Metabolism ReportsNutrigenomics in the management and prevention of metabolic disorders
2022, Role of Nutrigenomics in Modern-day Healthcare and Drug DiscoveryOrganic Acidemias and Disorders of Fatty Acid Oxidation
2020, Emery and Rimoin’s Principles and Practice of Medical Genetics and Genomics: Metabolic DisordersExperimental evidence of oxidative stress in patients with L-2-hydroxyglutaric aciduria and that L-carnitine attenuates in vitro DNA damage caused by D-2-hydroxyglutaric and L-2-hydroxyglutaric acids
2017, Toxicology in VitroCitation Excerpt :The mechanisms of the neurological symptoms presented by D-2-HGA and L-2-HGA patients are still poorly understood. However, considering that increased concentrations of D-2-HG and L-2-HG were associated with the appearance of neurological symptoms, these compounds may be potentially neurotoxic in these disorders (Van der Knaap et al., 1999a; Yilmaz, 2009; Patay et al., 2012; Marcel et al., 2012; Jovic et al., 2014). An in vitro study demonstrated that L-2-HG inhibits creatine kinase activity in cerebellum (da Silva et al., 2003).
L-2-hydroxyglutaric aciduria: REPORT on two cases
2014, Archives de PediatrieL-2 hydroxyglutaric aciduria: report of a Mexican-Mayan patient with the mutation c.569C>T and response to vitamin supplements and levocarnitine
2024, Tremor and Other Hyperkinetic Movements